Thalidomide and sensory neurotoxicity: A neurophysiological study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 11, 2008, Pages 1258-1261

  Zara, Gabriella ^a   Ermani, M ^a   Rondinone, R ^a   Arienti, S ^a   Doria, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; ANGIOGENESIS INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; FEMALE; HUMAN; LEG CRAMP; NERVE POTENTIAL; NEUROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; SENSORY NERVE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SURAL NERVE; TOUCH; CHEMICALLY INDUCED DISORDER; DISABILITY; DRUG EFFECT; MALE; MIDDLE AGED; NERVE DEGENERATION; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; SENSORY DYSFUNCTION;

ADULT; ANGIOGENESIS INHIBITORS; DISABILITY EVALUATION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; NERVE DEGENERATION; PAIN; PAIN MEASUREMENT; PARESTHESIA; PERIPHERAL NERVOUS SYSTEM DISEASES; SENSATION DISORDERS; SURAL NERVE; THALIDOMIDE; TOUCH;

EID: 55249098653     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.147892     Document Type: Article

References (20)

1. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005;10:107-14.
2. Hamanoue M, Middleton G, Wyatt S, et al. p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Moll Cell Neurosci 1999;14:28-40.
3. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide. Neurology 2007;69:573- 81.
4. Empl M, Renaud S, Erne B, et al. TNF-alpha expression in painful and non painful neuropathies. Neurology 2001;56:1371-7.
5. George A, Marziniak M, Schafers M, et al. Thalidomide treatment in cronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 2000;88:267-75.
6. Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002;119:1020-6.
7. Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004;72:403-9.
8. Ochonisky S, Verroust J, Bastuji-Garin S, et al. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994;130:66-9.
9. Briani C, Zara G, Rondinone R, et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004;62:2288-90.
10. Briani C, Zara G, Rondinone R, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity 2005;38:549-55.
11. Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve;24:1050-7.
12. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11:21-32.
13. Notermans NC, Wokke HJ, Lokhorst HM, et al. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994;117:1385-93.
14. Chapon F, Lechevalier B, Da Silva DC, et al. Neuropathies caused by thalidomide. Rev Neurol 1985;141:719-28.
15. Fullerton PM, O'Sullivan DJ. Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiat 1968;31:543-51.
16. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology 2002;59:1872.
17. Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003;60:877-8.
18. Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004;109:188-93.
19. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507-14.
20. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiolgical study. Neurology 2004;62:2291-3.